Metastatic breast cancer patient tests negative for COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Janice Cowden, a Florida resident who has metastatic breast cancer and symptoms of the novel coronavirus, has tested negative for COVID-19 after a lengthy process that involved being denied testing multiple times—despite her vulnerable status (The Cancer Letter, March 20).

Cowden, 62, was worried about having potentially exposed other patients at a fundraising event in late February. Two weeks ago, on March 21, she finally received a test. To be exact, she received two tests—one at a curbside testing facility, and one at her primary care provider.

It took 13 days for Cowden to receive the results from both tests. “The upside of two negative tests is that MD Anderson might be less likely to reschedule my PET/CT/Onc appointments again,” Cowden said.

Cowden’s symptoms have mostly subsided after a full month of not knowing whether she put others at risk. The delay indicates a nationwide response to COVID-19 that can be best described, in Cowden’s words, as “a total shit show.”

“That’s usually what we call metastatic breast cancer—just a total shit show. It’s very valid to use that term in relation to this virus too, because it truly is that,” Cowden said.

Cowden first developed symptoms of COVID-19 in early March—severe coughing, labored breathing, aches and a high fever of 103. There was a delay in testing, because her primary care physician and the emergency room didn’t have any tests.

“This whole experience has been one of extreme frustration and disappointment for me. There are so many other people who are just at the beginning of this,” Cowen said. “Clearly they’re not going to be getting their results, unless they’re inpatient, any faster—or unless they’re a health care worker at a facility.”

In Florida, where there are upwards of 8,000 confirmed cases of the virus, Gov. Ron DeSantis issued a statewide stay-at-home order April 1. On the day Cowden sought treatment at the ER at the direction of her primary care physician, her community held a St. Patrick’s Day celebration.

“It’s just so widespread in Florida. So, I look at this and I think, why is it so difficult for Americans in general to do what we need to do to lessen the spread of the disease?” Cowden said. “Those of us who’ve been immunocompromised due to disease treatment for breast cancer are used to having to socially isolate. If they could just do it for a short time, then it would change that entire trajectory pattern.”

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login